CADTH has received notice of a pending submission from GSK for umeclidinium (Incruse Ellipta) for patients with chronic obstructive pulmonary disease.  For information about the patient input process or for additional instructions, please see the Patient Input page of the CADTH website. Note that only patient groups may submit input.

For more details, go to: http://www.cadth.ca/en/products/cdr/patient-group-input/